Sucampo Pharmaceuticals — FY2013 Earnings Presentation
26 slides from Sucampo Pharmaceuticals's earnings presentation, Feb 26, 2014
Slide 1: Fourth Quarter and Full Year 2013 Results
Fourth Quarter and Full Year 2013 Results February 26, 2014 e 3 SUCAMPO The Science of Innovation
Slide 2: Introductions and Forward-Looking Statements
luctions and Forward- | Statements Silvia Taylor Senior Vice President, Investor Relations and Corporate Communications ¢ 3 SUCAMPO The Science of Innovation
Slide 3: Agenda
Agenda Introductions and Forward-Looking Statements Silvia Taylor Highlights of the Quarter Ryuji Ueno, M.D., Ph.D., Ph.D. AMITIZA® (lubiprostone) & RESCULA® (unoprostone isopropyl) Commercial Update Stanley G. Miele Pipeline and R&D Update Taryn Losch-Beridon Financial Performance Cary J. Claiborne
Slide 4: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ m
Slide 5: Ryuji Ueno, M.D., Ph.D., Ph.D.
Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder 3 SUCAMPO The Science of Innovation
Slide 6: 2013 Highlights
2013 Highlights 2013: Significant Growth + Expansion of business: new indications, new markets + Profitable + Increase in revenue + Efficient use of capital + Progress in clinical development AMITIZA® RESCULA® United States Japan Europe United States + Approval for OIC | + Strong + Launched for CIC
Slide 7: Leadership Transition
Leadership Transition Ryuji Ueno, M.D., Ph.D., Ph.D. to step down as CEO, Chairman and Director on March 3, 2014 + Will step down as CSO on March 31, 2014 + Will consult to Sucampo as Co-founder, Chairman Emeritus, and Scientific Advisor on transition, pipeline development and other strategic activi
Slide 8: Financial Highlights 2013
Financial Highlights 2013 Exceeded 2013 Earning Guidance of $3-5M of Net Income + Net income excluding special items of $9.4M for 2013, $0.22 cents per share 2014 Guidance: Expect to be Profitable + Will provide more specific guidance at later time $ sucAMPO 8 The Science of Innovation
Slide 9: Stanley G. Miele
Stanley G. Miele President, Sucampo Pharma Americas, LLC and SVP, Sales and Marketing td 3 SUCAMPO The Science of Innovation
Slide 10: AMITIZA U.S.
AMITIZA U.S. Continued AMITIZA YOY Growth + Q4: Strongest quarter ever for AMITIZA + Net sales growth of 5% for Q4 + TRx growth of 6% for Q4 + Calendar year high of 1.3M TRx in 2013 AMITIZA * TRx up 5% YoY through December YTD" Market Growth Accelerating + Class up almost 7% for 1H 2014 vs 1H 2013 O
Slide 11: RESCULA U.S. Overview
RESCULA U.S. Overview RESCULA Commercial Strategy + Implemented new commercial strategy for RESCULA + Focus on current RESCULA prescribers + Contract sales representatives are spending 20% of time calling on current RESCULA prescribers + Belief in value of continued development + Excited about the d
Slide 12: AMITIZA Global Snapshot
AMITIZA Global Sna Japan Continued success; sales continue to be above our and Abbott's expectations AMITIZA sales in Japan contributed $16 million to topline in 2013 Abbott applying more. than half of its detailing efforts in Japan to AMITIZA 2 week limitation removed in December Europe * OIC filin
Slide 13: Pipeline and R&D Update
ine and R&D Update Taryn Losch-Beridon Vice President, Clinical Development ¢ 13 > SUCAMPO The Science of Innovation
Slide 14: Lubiprostone Clinical Development & Life Cycle Management
Lubiprostone Clinical Development & Life Cycle Management Pediatric Functional Constipation + Initiated global P3 clinical program for lubiprostone in children and adolescents aged 6 to 17 years with pediatric functional constipation + Takeda is funding 70% of development costs + Anticipate the firs
Slide 15: Sucampo Prostone Pipeline Key Highlights (cont)
Sucampo Prostone Pipeline Key Highlights (cont) lon Channel Activators for Lumbar Spinal Stenosis Lumbar Spinal Stenosis (LSS) + Degenerative change in lumbar spine; unmet medical need with limited treatment options globally* + Prevalence: ~400,000 Americans, most >60 years of age"! + Top-line resul
Slide 16: Financial Performance
| Performance== Cary J. Claiborne Chief Financial Officer ¢ 3 SUCAMPO The Science of Innovation
Slide 17: Revenue Highlights ($M)
fevenue Highlights ($M) $50.7 $52.1 $21.5 $20.4 $164 FY-12 FY-13 FY-12 FY-13 FY-12 FY-13 FY-12 FY-13 Total Revenues R&D Revenues Product Royalty Product Sales Revenues Revenues $ sucAMPO 7 *Co-promotion, contract and collaboration revenue also are components of revenue. The Science of Innovation
Slide 18: Net Sales ($M)
Net Sales* ($M) 43.8% $282.1 $271.9 +4.6% $74.6 $78.0 Q412 Q413 FY-12 FY-13 $ sucAMPO ‘8 *As reported by Takeda for royalty calculation purposes The Science of Innovation
Slide 19: Income Statement Items
items Revenue $89.6 $81.5 9.9% Bcpenses | Cost of goods sold $12.4 $3.0 309.3% R&D expense $21.5 $21.3 1.1% G&A expense $25.4 $30.2 (15.7%) S&M expense $21.4 $18.7 12.7% Income from operations $9.2 $8.3 | 10.6% Non-operating income/(expense), net $1.2 ($0.6) F Tax provision (63.9) | 629) 34.7% GAAP
Slide 20: EPS and Net Income Reconciliation
EPS GAAP Diluted EPS $ 0.05 | $ 0.15 Difference® 0.01 0.07 Non-GAAP Diluted EPS that exclude RESCULA inventory/samples non-cash write- — as off Net income GAAP net income? $ 2,163 | $ 6,419 Difference 267 2,983 Non-GAAP net income that excludes RESCULA inventory/samples non-cash write- 2,420 9,402 o
Slide 21: Financial Summary
Financial Summary Solid Financial Performance in 2013 + Grew total Net Revenue by 10% in 2013 + Generated non-GAAP Net Income of $9.4M, up 94% over 2012 + Exceeded high end of November non-GAAP Net Income guidance of $5M by 88% + Ended the year with $96M in Cash, Cash equivalents and Investments Pos
Slide 22: Ryuji Ueno, M.D., Ph.D., Ph.D.
Ryuji Ueno, M.D., Ph.D., Ph.D. Chairman, Chief Executive Officer, Chief Scientific Officer, and Co-founder ¢ 22 ? SUCAMPO The Science of Innovation
Slide 23: ¢
¢ 23 9 SUCAMPO The Science of Innovation
Slide 24: References
References IMs Smart View, NPA Report, client Factored Numbers IMS, NPA weekly data, DART Camilleri M. Opiold.induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011 May;106(5):835-42 Clearview Analysis 2008 1 2 a 4 5, IMS Smart View, RAPID Weekly, Client Factored Nu
Slide 25: Pipeline
— Pipeline _abiorstne| aa lon Channel aa ator ¥ Completed Q In Progress <i) co eee os < Hi Obtain approval of OIC sNDA: 1Q 2013 $10M milestone payment upon commercial launch of OIC Ongoing: Pursue strategic alliances; new AMITIZA indications/territories Grow sales in Japan in 2013 Submit for regulat
Slide 26: Stage of Clinical Development
CLINICAL FOCUS STAGE OF CLINICAL DEVELOPMENT LEAD COMPOUNDS PRECLINICAL | PHASE 1 PHASE 2 PHASE 3 P2Poc 2H14 4013 Phase 1b 1014 MISUCCESSFULLY COMPLETED [PROJECTED START ONGOING ¢ 26 ? SUCAMPO *Co-developing with R-Tech Ueno, Ltd ‘The Science of Innovation
Sucampo Pharmaceuticals — FY2013 Earnings Presentation on 6ix